Your browser doesn't support javascript.
loading
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
Eyre, Toby A; Fox, Christopher P; Boden, Ali; Bloor, Adrian; Dungawalla, Moez; Shankara, Paneesha; Went, Richard; Schuh, Anna H.
Affiliation
  • Eyre TA; Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.
  • Fox CP; Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Boden A; Department of Haematology, United Lincolnshire Hospitals NHS Trust, Lincoln, UK.
  • Bloor A; Department of Haematology, The Christie Hospital NHS Trust, Manchester, UK.
  • Dungawalla M; Department of Haematology, Milton Keynes Hospital, Milton Keynes, UK.
  • Shankara P; Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, UK.
  • Went R; Department of Clinical Haematology, The Rotherham NHS Foundation Trust, Rotherham, UK.
  • Schuh AH; Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.
Br J Haematol ; 184(4): 667-671, 2019 02.
Article in En | MEDLINE | ID: mdl-29468637
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Purines / Remission Induction / Tumor Suppressor Protein p53 / Quinazolinones / Rituximab Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Purines / Remission Induction / Tumor Suppressor Protein p53 / Quinazolinones / Rituximab Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Year: 2019 Type: Article